HRP20180373T1 - Derivat piridona i lijek koji sadrži derivat piridona - Google Patents
Derivat piridona i lijek koji sadrži derivat piridona Download PDFInfo
- Publication number
- HRP20180373T1 HRP20180373T1 HRP20180373TT HRP20180373T HRP20180373T1 HR P20180373 T1 HRP20180373 T1 HR P20180373T1 HR P20180373T T HRP20180373T T HR P20180373TT HR P20180373 T HRP20180373 T HR P20180373T HR P20180373 T1 HRP20180373 T1 HR P20180373T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- optionally substituted
- image
- atom
- alkoxy
- Prior art date
Links
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title claims 12
- 239000003814 drug Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 125000005694 substituted alkenylalkyl group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000005038 alkynylalkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 208000035474 group of disease Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012692 Diabetic uveitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Derivat piridona ili njegova sol izražen formulom (I),
[image]
naznačen time da prsten A predstavlja aril, hetroaril ili grupu izraženu sljedećom formulom (a):
[image]
(gdje Z1 i Z2 svaki zasebno predstavljaju –CH2- ili –O- i n1 predstavlja cijeli broj od 1 do 3), R1 predstavlja atom vodika, atom halogena, hidroksil grupu, cijano grupu, nitro grupu, C1-C6 haloalkil grupu, karboksilnu grupu, po izboru supstituiranu C1-C6 alkoksi grupu, po izboru supstituiranu C1-C6 alkoksikarbonil grupu, po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloheskilalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu hetreoarilalkil grupu, po izboru supstituiranu C2-C6 alkenil grupu, po izboru supstituiranu alkenilalkil grupu, po izboru supstituiranu cikloalkenil grupu, po izboru supstituiranu cikloalkenilalkil grupu, po izboru supstituiranu heterocikloalkenilu, po izboru supstituiranu heterocikloalkenilalkil grupu, po izboru supstituiranu C2-C6 alkinil grupu ili po izboru supstituiranu alkinilalkil grupu ili- J1-X1-R5 {gdje J1 predstavlja jedinu vezu, alkilen, alkenilen ili alkinilen, X1 predstavlja jedinu vezu, atom kisika, atom sulfora, SO, SO2, -CO-, NR6-, -NR6SO2-, -SO2NR6-, -NR6CO-, -CONR6-, -NR6COO-, -OCONR6-, -NR6CONR7-, or -NR6SO2NR7- (gdje R6 i R7 svaki zasebno predstavljaju atom vodika ili C1-C6 alkil grupu),
R5 predstavlja atom vodika, trifluormetil grupu, po izboru supstituiranu C1-C6 alkil grupu, po izboru supstituiranu C1-C2 alkoksi grupu, po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, grupu koja je izražena sljedećom formulom (b):
[image]
(gdje n2 predstavlja cijeli broj od 1 do 3 i n3 predstavlja cijeli broj od 0 do 3), po izboru supstituiranu aril grupu, po izboru supstituiranu aralkilnu grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu hetreoarilalkil grupu, po izboru supstituiranu C2-C6 alkenil grupu, po izboru supstituiranu alkenilalkil grupu, po izboru supstituiranu C2-C6 alkenil grupu, po izboru supstituiranu alkenilalkil grupu, po izboru supstituiranu C2-C6 alkinil grupu, po izboru supstituiranu alkinilalkil grupu},
R2 predstavlja atom vodika, atom halogena, cijano grupu, nitro grupu, C1-C6 haloalkil grupu, karboksil grupu, po izboru supstituiranu C1-C6 alkil grupu, C1-C6 alkoksi grupu, C1-C6 alkoksikabonil grupu, po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloheksialkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil gupu, po izboru supstituiranu C2-C6 alkenil grupu, po izboru supstituiranu alkenilalkil grupu po izboru supstituiranu heterocikloalkenil grupu, po izboru supstituiranu heterocikloalkenilalkil grupu, po izboru supstituiranu C2-C6 alkinil grupu, po izboru supstituiranu alkinilalkil grupu,
R3 predstavlja atom vodika, atom halogena ili C1-C6 alkil grupu, i
R4 predstavlja atom vodika, atom halogena, cijano grupu, C1-C6 haloalkil grupu, C1-C6 alkoksi grupu, hidroksimetil grupu, C1-C6 alkil grupu ili C2-C6 alkenil grupu]
gdje su zamjene za
po izboru supstituiranu C1-C6 alkil grupu,
po izboru supstituiranu C2-C6 alkenil grupu,
po izboru supstituiranu alkenilalkil grupu,
po izboru supstituiranu C2-C6 alkinil grupu,
po izboru supstituiranu alkinilalkil grupu,
po izboru supstituiranu cikloalkil grupu,
po izboru supstituiranu cikloalkilalkil grupu,
po izboru supstituiranu heterocikloalkil grupu,
po izboru supstituiranu heterocikloalkilalkil grupu,
po izboru supstituiranu heterocikloalkenil grupu, i
po izboru supstituiranu heterocikloalkenilalkil grupu,
po izboru supstituiranu cikloheksilalkilalkil grupu,
po izboru supstituiranu cikloalkenil grupu, i
po izboru supstituiranu cikloalkenilalkil grupu izabrane iz:
grupe hidroksila, atoma halogena, cijano grupe, nitro grupe, trifluormetil grupe, C1-C6 alkoksi grupe po izboru supstituirane s hidroksil grupom, atoma halogena, cijano grupe, nitro grupe ili C1-C6 alkoksi grupe, cijanoalkil grupe, karboksil grupe, C1-C6 akloksikarbonil grupe, - NR8R9 {gdje R8 i R9 svaki zasebno predstavljaju atom vodika, C1-C6 alkil grupu, formil grupu, acil grupu po izboru supstituiranu s ahidroksil grupom, atom halogena, cijano grupu, nitro grupu ili C1-C6 alkoksi grupu, -CONR10R11 [gdje R10 i R11 svaki zasebno predstavljaju atom vodika, C1-C6 alkil grupu, po izboru zamijenjenu s R12 (gdjeR12 predstavlja C1-C6 alkil grupu, C1-C6 alkoksi grupu ili atom halogena), heteroaril grupu po izboru supstituiranu s R12 (R12je definiran kako je naprijed navedeno) ili tvore heterolitički prsten koji sadrži nitrogen zajedno s atomom nitrogena na koji su vezani R10 i R11], cikloalkil grupu ili tvore heterolitički prsten koji sadrži nitrogen zajedno s atomom nitrogena na koji su vezani R8 i R9}, ili -OCOR13 [gdje R13 predstavlja C1-C6 alkil grupu, aril grupu po izboru supstituiranu s R12 (R12 je definiran kako je naprijed navedeno), ili -NR14R15 (gdje R14 i R15 svaki zasebno predstavljaju atom vodika, C1-C6 alkil grupu, aril grupu po izboru supstituiranu s R12 (R12je definiran kako je naprijed navedeno), heteroaril grupu po izboru supstituiranu s R12 (R12koji je definiran kako je naprijed navedeno) ili tvore heterolitički prsten koji sadrži nitrogen s atomom nitrogena na koji su vezani R14 i R15);
gdje su zamjene za
po izboru supstituiranu aril grupu,
po izboru supstituiranu aralkil grupu,
po izboru supstituiranu heteroaril grupu, i
po izboru supstituiranu heteroarilalkil grupu izabrane iz:
grupe hidroksila, atoma halogena, cijano grupe, nitro grupe, trifluormetil grupe, po izboru supstituirane C1-C6 alkil grupe kako je opisano gore, C1-C6 alkoksi grupe po izboru supstituirane s ahidroksil grupom, atoma halogena, cijano grupe, nitro grupe ili C1-C6 akloksi grupe, cijanoalkil grupe, karboksil grupe, C1-C6 alkoksikarboksil grupe, -NR14R15 (gdje su R14 i R15 definirani kako je naprijed navedeno), -OCOR13 (gdje je R13definiran kako je naprijed navedeno);
gdje su zamjene za
po izboru supstituiranu C1-C6 alkoksi grupu,
po izboru supstituiranu acil grupu, i ,
po izboru supstituiranu alkoksikarbonil grupu izabrane iz:
grupe hidroksila, atoma halogena, cijano grupe, nitro grupe, C1-C6 alkoksi grupe.
2. Derivat piridona ili njegova sol prema patentnom zahtjevu 1, naznačena time da je prsten A u formuli (I) arili ili heteroaril.
3. Derivat piridona ili njegova sol prema patentnom zahtjevu 1 ili 2, naznačen time da je R1 u formuli (I) atom halogena, cijano grupa, C1-C6 alkil grupa, C1-C6 alkoksi grupa, ili -J1-X1-R5 (gdje J1 predstavlja jedinu vezu ili alkilen, X1 predstavlja jedinu vezu ili atom kisika ili atom sulfora i R5 predstavlja po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil grupu) gdje su mogući supstituti definirani kao u patentnom zahtjevu 1.
4. Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 3, naznačen time da je R2 u formuli (I) atom vodika, atom halogena, C1-C6 alkoksi grupa,ili C1-C6 alkil grupa.
5. Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 4, naznačen time da je R3 u formuli (I) atom vodika, atom fluora ili metil grupa.
6. Derivat piridona ili njegova sol prema patentnom zahtjevu 5 naznačen time da u formuli (I):
R1 predstavlja atom vodika, cijano grupu, C1-C6 alkil grupu, C1-C6 alkil grupu alkoksi grupu ili -J1-X1-R5 (gdje J1 predstavlja jedinu vezu ili alkilen, X1 predstavlja jedinu vezu, atom kisika ili atom sulfora i R5 predstavlja po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil grupu),
R2 predstavlja atom vodika, atom halogena, C1-C6 alkoksi grupu ili C1-C6 alkil grupu, i
R3 predstavlja atom vodika, atom fluora ili metil gupu,
gdje su mogući supstituti definirani kao u patentnom zahtjevu 1.
7. Derivat piridona ili njegova sol prema patentnom zahtjevu 6 naznačen time da u formuli (I):
R1 predstavlja atom halogena, cijano grupu, metil gupu, C1-C6 alkoksi grupu ili -J1-X1-R5 (gdje J1 predstavlja jedinu vezu ili alkilen, X1 predstavlja jedinu vezu, atom kisika ili atom sulfora i R5 predstavlja po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil grupu),
R2 predstavlja atom vodika, atom halogena, metoksi grupu ili metil grupu, i
R3 predstavlja atom vodika, atom fluora ili metil grupu,
gdje su mogući supstituti definirani kao u patentnom zahtjevu 1.
8. Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 7, naznačen time da je R4 u formuli (I) atom halogena, cijano grupa, C1-C6 haloalkil grupa, C1-C6 alkoksi grupa, hidrometil grupa, C1-C6 alkil grupa ili C2-C6 alkenil grupa.
9. Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 8, naznačen time da je R4 u formuli (I) metil grupa.
10. Derivat piridona ili njegova sol prema patentnim zahtjevima 1, 2, 7 i 9 naznačen time da je komponenta predstavljena formulom (I) izabrana iz:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
11. Farmaceutski pripravak naznačen time da sadrži derivat piridona ili njegovu sol kao aktivni sastojak, prema bilo kojem od patentnih zahtjeva 1 do 10.
12. Farmaceutski pripravak prema patentnom zahtjevu 11 naznačen time da je farmaceutski pripravak topljivi TNF-α inhibitor.
13. Farmaceutski pripravak prema patentnom zahtjevu 11 za upotrebu u prevenciji ili liječenju bolesti povezanih s TNF-α, naznačen time da je bolest povezana s TNF-α jedna ili više bolest iz grupe bolesti koja uključuje reumatoidni artritis, posorijatični artritis, sistemski eritemski lupus (SLE), lupus nefritis, sistemsku skelodermiju, lokalnu skelodermiju, Sjorgenov sindrom, polimiozitis, dermatomiozitis, ulcerativni kolitis, Kronovu bolest, Behcetovu bolest, multiplu sklerozu, arteriosklerozu, mijasteniju gravis, ankilozantni spondilitis, dijabetis, arteriosklerozu, sepsu, akutnu infekciju, astmu, kroničnu opstruktivnu bolest pluća (COPD), atopijski dermatitis, kontaktni dermatitis, psorijazu, akne, osteosporozu, opekline, napad ili odbacivanje povezano s transplantacijom organa ili tkiva, vrućicu, anemiju, rak, paradontozu, glaukom, dijabetičke komplikacije i uveitis.
14. Farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13, naznačen time da je bolesti povezana s TNF-α kožna bolest.
15. Farmaceutski pripravak za upotrebu prema patentnom zahtjevu 14, naznačen time da je kožna bolest jedna ili više bolest iz grupe bolesti koja uključuje lokalnu skelodermiju, atopijski dermatitis, kontaktni dermatitis, psorijazu, akne.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011270492 | 2011-12-09 | ||
| EP12854960.7A EP2789607B1 (en) | 2011-12-09 | 2012-12-07 | Pyridone derivative and medicine containing same |
| PCT/JP2012/081736 WO2013085017A1 (ja) | 2011-12-09 | 2012-12-07 | ピリドン誘導体およびそれを含有する医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180373T1 true HRP20180373T1 (hr) | 2018-04-06 |
Family
ID=48574371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180373TT HRP20180373T1 (hr) | 2011-12-09 | 2018-03-02 | Derivat piridona i lijek koji sadrži derivat piridona |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9447072B2 (hr) |
| EP (1) | EP2789607B1 (hr) |
| JP (1) | JP6091427B2 (hr) |
| CN (1) | CN103987706B (hr) |
| AU (1) | AU2012349288B2 (hr) |
| CA (1) | CA2858164C (hr) |
| CY (1) | CY1120101T1 (hr) |
| DK (1) | DK2789607T3 (hr) |
| ES (1) | ES2663246T3 (hr) |
| HR (1) | HRP20180373T1 (hr) |
| HU (1) | HUE038523T2 (hr) |
| LT (1) | LT2789607T (hr) |
| NO (1) | NO2789607T3 (hr) |
| PL (1) | PL2789607T3 (hr) |
| PT (1) | PT2789607T (hr) |
| RS (1) | RS57107B1 (hr) |
| SI (1) | SI2789607T1 (hr) |
| TW (1) | TWI568726B (hr) |
| WO (2) | WO2013085017A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447072B2 (en) * | 2011-12-09 | 2016-09-20 | Kaken Pharmaceutical Co., Ltd. | Pyridone derivative and pharmaceutical containing same |
| CA2913858C (en) * | 2013-06-07 | 2021-07-20 | Kaken Pharmaceutical Co., Ltd. | (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same |
| AU2014275836A1 (en) * | 2013-06-07 | 2015-12-24 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining platelet function |
| KR102409533B1 (ko) * | 2016-09-23 | 2022-06-15 | 가껭세이야꾸가부시기가이샤 | (r)-5-(3,4-디플루오로페닐)-5-[(3-메틸-2-옥소피리딘-1(2h)-일)메틸]이미다졸리딘-2,4-디온의 제조 방법 및 그 제조를 위한 중간체 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022801A1 (fr) | 2001-09-07 | 2003-03-20 | Kaken Pharmaceutical Co., Ltd. | Derives d'acide hydroxamique inverse |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| EP1546109A4 (en) * | 2002-10-04 | 2005-11-09 | Bristol Myers Squibb Co | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE) |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| EP1778676B1 (en) | 2004-07-16 | 2010-08-25 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PE20071240A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| US8450355B2 (en) * | 2008-09-24 | 2013-05-28 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory diseases |
| US8859529B2 (en) * | 2008-09-24 | 2014-10-14 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| WO2010054278A2 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US9447072B2 (en) * | 2011-12-09 | 2016-09-20 | Kaken Pharmaceutical Co., Ltd. | Pyridone derivative and pharmaceutical containing same |
-
2012
- 2012-12-07 US US14/363,198 patent/US9447072B2/en active Active
- 2012-12-07 EP EP12854960.7A patent/EP2789607B1/en active Active
- 2012-12-07 AU AU2012349288A patent/AU2012349288B2/en active Active
- 2012-12-07 WO PCT/JP2012/081736 patent/WO2013085017A1/ja active Application Filing
- 2012-12-07 CN CN201280060275.3A patent/CN103987706B/zh active Active
- 2012-12-07 SI SI201231248T patent/SI2789607T1/en unknown
- 2012-12-07 HU HUE12854960A patent/HUE038523T2/hu unknown
- 2012-12-07 RS RS20180431A patent/RS57107B1/sr unknown
- 2012-12-07 PT PT128549607T patent/PT2789607T/pt unknown
- 2012-12-07 JP JP2013548305A patent/JP6091427B2/ja active Active
- 2012-12-07 NO NO12854960A patent/NO2789607T3/no unknown
- 2012-12-07 CA CA2858164A patent/CA2858164C/en active Active
- 2012-12-07 WO PCT/JP2012/081735 patent/WO2013085016A1/ja active Application Filing
- 2012-12-07 TW TW101146223A patent/TWI568726B/zh active
- 2012-12-07 ES ES12854960.7T patent/ES2663246T3/es active Active
- 2012-12-07 DK DK12854960.7T patent/DK2789607T3/en active
- 2012-12-07 LT LTEP12854960.7T patent/LT2789607T/lt unknown
- 2012-12-07 PL PL12854960T patent/PL2789607T3/pl unknown
-
2016
- 2016-08-09 US US15/232,000 patent/US10000476B2/en active Active
-
2018
- 2018-03-02 HR HRP20180373TT patent/HRP20180373T1/hr unknown
- 2018-03-02 CY CY20181100263T patent/CY1120101T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2789607T (lt) | 2018-03-26 |
| US10000476B2 (en) | 2018-06-19 |
| AU2012349288B2 (en) | 2016-12-01 |
| TWI568726B (zh) | 2017-02-01 |
| JPWO2013085016A1 (ja) | 2015-04-27 |
| TW201336832A (zh) | 2013-09-16 |
| EP2789607A1 (en) | 2014-10-15 |
| RS57107B1 (sr) | 2018-06-29 |
| WO2013085016A1 (ja) | 2013-06-13 |
| ES2663246T3 (es) | 2018-04-11 |
| CA2858164A1 (en) | 2013-06-13 |
| JP6091427B2 (ja) | 2017-03-08 |
| WO2013085017A1 (ja) | 2013-06-13 |
| AU2012349288A1 (en) | 2014-07-24 |
| CY1120101T1 (el) | 2018-12-12 |
| US20160340349A1 (en) | 2016-11-24 |
| US9447072B2 (en) | 2016-09-20 |
| EP2789607A4 (en) | 2015-08-05 |
| CN103987706A (zh) | 2014-08-13 |
| CA2858164C (en) | 2020-12-15 |
| EP2789607B1 (en) | 2018-02-07 |
| PL2789607T3 (pl) | 2018-08-31 |
| CN103987706B (zh) | 2016-06-29 |
| PT2789607T (pt) | 2018-03-22 |
| AU2012349288A2 (en) | 2014-08-07 |
| SI2789607T1 (en) | 2018-04-30 |
| HUE038523T2 (hu) | 2018-10-29 |
| DK2789607T3 (en) | 2018-03-12 |
| NO2789607T3 (hr) | 2018-07-07 |
| US20150166506A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180373T1 (hr) | Derivat piridona i lijek koji sadrži derivat piridona | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| MX2009008509A (es) | Compuesto de anillo puenteado-aza. | |
| HRP20180212T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| HRP20161127T1 (hr) | Derivati indazolil triazola kao inhibitori irak | |
| JP2015531366A5 (hr) | ||
| JP2016512520A5 (hr) | ||
| JP2016506960A5 (hr) | ||
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| EP4272824A3 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| NZ705881A (en) | Heteroaryl inhibitors of pde4 | |
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| PH12014501680A1 (en) | Arylalkyloxy pyrimidine derivative, pesticide for agricultural and horticultural use containing arylalkyloxy pyrimidine derivative as active ingredient, and use of same | |
| RS54208B1 (en) | NEMATOCIDE SULFONAMIDES | |
| JP2016508505A5 (hr) | ||
| RS52313B (en) | MYTHOSIS PROGRESS INHIBITION UNITS | |
| PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
| RS51985B (en) | NEW IMIDASOLONE DERIVATIVES, THEIR PREPARATION FOR MEDICINES, PHARMACEUTICAL FORM AND THEIR USE AS PROTEIN KINASES SPECIFICALLY CDC7 | |
| JP2013514384A5 (hr) | ||
| SI3083605T1 (en) | COMPOUNDS OF FLUOROFENYL PIRAZOLE | |
| SA519400868B1 (ar) | معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد | |
| RU2015121045A (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстеразы |